Contemporary Concepts in Prostate Cancer

Contemporary Concepts in Prostate Cancer is an online resource for professionals within the oncology space, from medical oncologists and pathologists to oncology nurses and mental health experts. Prostate cancer is the most common cancers in men within the United States beyond skin cancer, and is most likely to develop in older and non–Hispanic Black men. Due to this, CancerNetwork® has created a central hub to inform oncology professionals about the latest non-clinical developments in patient care. Contemporary Concepts in Prostate Cancer also provides the most recent findings regarding patient-specific issues such as the psychosocial impact of prostate cancer, sexual health, disparities in care and outcomes, survivorship and quality of life, and financial toxicity.

Contemporary Concepts in Prostate Cancer showcases articles, podcasts, and video interviews with key opinion leaders in the field to keep you up to date with the latest developments in the prostate oncology space.

Management of Cancer Disparities

Management of Financial Toxicity

Management of Psychosocial Concerns

Management of Sexual Health

Guideline Updates

Management of Survivorship & Quality of Life

Latest From Contemporary Concepts in Prostate Cancer

PSMA PET Agent Flotufolastat F 18 Added to NCCN Prostate Cancer Guidelines

July 26 2023, 4:00pm

Flotufolastat F 18 is indicated for use in imaging PSMA-positive prostate cancer lesions in patients who are likely to have metastatic disease and may be able to undergo initial definitive therapy, as well as those who may have recurrent disease.

Despite Presenting With More Aggressive Disease, Black Vs White Men With Prostate Cancer Have Improved Outcomes Following Radiotherapy

October 20 2022, 6:00pm

A meta-analysis found Black men who undergo radiotherapy for localized prostate cancer have better outcomes in terms of biochemical recurrence, distant metastases, and prostate cancer-specific mortality than White men despite presenting with more aggressive disease.

PSA Screening Associated With Prostate Cancer–Specific Mortality Risk Reduction Among Black and White US Veterans

September 2 2022, 4:00pm

Findings from a study revealed a notable reduction in the risk of prostate cancer–specific mortality in Black United States veterans who underwent prostate-specific antigen screening, highlighting the potential importance of undergoing annual screenings in this patient population.

Baseline Benign Prostatic Hyperplasia Symptoms Warrant Consideration When Choosing Treatment in Early-Stage Prostate Cancer

August 31 2022, 2:00pm

Investigators highlighted that when determining a treatment strategy for patients with early-stage prostate cancer, baseline benign prostate hyperplasia symptoms should be taken into consideration.

Enzalutamide Associated with Worsened Cognitive/Physical Function but Not Overall HQL in mHSPC

February 24 2022, 5:00pm

A health-related quality of life assessment found an association between worsened self-reported fatigue, cognitive function, and physical function, with enzalutamide treatment for patients with metastatic, hormone-sensitive prostate cancer but improved deterioration-free survival for overall health and quality of life.

High Rates of Significant Depression Identified in Prostate Cancer

February 16 2022, 9:00pm

Patients with prostate cancer commonly have significant depression, highlighting a need for screenings in those with poor social determinants of health, concomitant disability, and advanced disease.

Meta-Analysis Indicates Black Individuals With Prostate Cancer May Have Better Outcomes in Radiation Therapy Clinical Trials vs White Patients

January 14 2022, 7:00pm

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.

NCCN Reverses Guideline Recommendation, States Active Surveillance Is Preferred Option for Low-Risk Prostate Cancer

December 3 2021, 7:00pm

The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.

PSA Testing Increased for Prostate Cancer Following Revised National Guidelines from 2017 by US Preventive Services Task Force

November 12 2021, 9:00pm

PSA testing rates for prostate cancer increased among men after the US Preventive Services Task Force released updated guidance in 2017 that reversed the recommendations from previous guidance in 2012.

Racial and Ethnic Disparities Identified in Those With a High PSA Undergoing MRI Imaging for Prostate Cancer

November 11 2021, 7:00pm

Investigators noted evident racial and ethnic disparities among patients with high prostate-specific antigen levels who received subsequent prostate MRI imaging.